ImmuCell (ICCC) Stock Price, News & Analysis

Company Overview

ImmuCell Corporation (NASDAQ: ICCC) is a Maine‐based biotechnology company specializing in immunological products for livestock health. Since its founding in the 1970s, the company has focused on developing solutions that enhance disease resistance and overall well‐being in dairy and beef cattle. ImmuCell’s portfolio is built on proprietary technologies designed to support passive immunity transfer in neonatal calves and to protect against common bacterial infections in adult cows.

The company’s flagship offering, First Defense, is a colostrum supplement formulated to reinforce calves’ immune systems shortly after birth. By supplying key antibodies and bioactive proteins, this product aims to reduce morbidity and mortality associated with scours and other early‐life infections. In addition, ImmuCell markets a range of mastitis prevention and therapeutic products that target intramammary infections, helping dairy producers maintain udder health and optimize milk quality.

ImmuCell distributes its products through a network of veterinary clinics, feed dealers and agricultural cooperatives across the United States, Canada and select international markets. The company partners with veterinary professionals to provide educational support, technical training and on‐farm implementation advice, ensuring its products are integrated into herd health protocols. By combining research‐driven formulations with practical guidance, ImmuCell positions itself as a trusted collaborator in the global livestock health arena.

Headquartered in Portland, Maine, ImmuCell operates state‐of‐the‐art research facilities dedicated to vaccine and immunology research. Under the leadership of CEO David Davies and a seasoned management team, the company continues to invest in product innovation and regulatory compliance. ImmuCell’s board comprises industry veterans in animal health, regulatory affairs and agricultural economics, reflecting a governance structure aimed at long‐term growth and scientific excellence.

Key Stats

• Today's Range: $6.55 to $6.86
• 50-Day Range: $4.91 to $7.60
• 52-Week Range: $3.34 to $7.60
• Volume: 5,994 shs
• Average Volume: 24,930 shs
• Market Capitalization: $59.94 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

ImmuCell Stock Analysis - MarketRank™

ImmuCell scored higher than 6% of companies evaluated by MarketBeat, and ranked 905th out of 922 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: N/A
• Analyst Rating: N/A

Consensus Rating

There is not enough analysis data for ImmuCell.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: N/A

Price to Earnings Ratio vs. the Market

The P/E ratio of ImmuCell is -94.70, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of ImmuCell is -94.70, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

ImmuCell has a P/B Ratio of 2.15. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

0.13% of the float of ImmuCell has been sold short.

Short Interest Ratio / Days to Cover

ImmuCell has a short interest ratio ("days to cover") of 0.2, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in ImmuCell has recently increased by 28.07%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

ImmuCell does not currently pay a dividend.

Dividend Growth

ImmuCell does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

0.13% of the float of ImmuCell has been sold short.

Short Interest Ratio / Days to Cover

ImmuCell has a short interest ratio ("days to cover") of 0.2, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in ImmuCell has recently increased by 28.07%, indicating that investor sentiment is decreasing significantly.

News and Social Media

• Score: 2.3 / 5
• News Sentiment: N/A

News Sentiment

ImmuCell has a news sentiment score of 1.11. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.57 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 1 news article for ImmuCell this week, compared to 1 article on an average week.

Company Ownership

• Score: 0.0 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, ImmuCell insiders have not sold or bought any company stock.

Percentage Held by Insiders

Only 6.60% of the stock of ImmuCell is held by insiders.

Percentage Held by Institutions

Only 13.47% of the stock of ImmuCell is held by institutions.

ICCC Stock Analysis - Frequently Asked Questions

How have ICCC shares performed this year?

ImmuCell's stock was trading at $5.15 at the beginning of the year. Since then, ICCC shares have increased by 28.7% and is now trading at $6.63.

How were ImmuCell's earnings last quarter?

ImmuCell Corporation (NASDAQ:ICCC) posted its quarterly earnings results on Wednesday, May, 14th. The biotechnology company reported $0.16 earnings per share for the quarter. The biotechnology company had revenue of $8.07 million for the quarter. ImmuCell had a negative trailing twelve-month return on equity of 1.02% and a negative net margin of 1.00%.
Read the conference call transcript.

How do I buy shares of ImmuCell?

Shares of ICCC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of ImmuCell own?

Based on aggregate information from My MarketBeat watchlists, some other companies that ImmuCell investors own include VBI Vaccines (VBIV), Sorrento Therapeutics (SRNE), Altimmune (ALT), Biocept (BIOC), ImmunoGen (IMGN), Novavax (NVAX) and Pfizer (PFE).

Company Calendar

• Last Earnings: 5/14/2025
• Today: 7/08/2025
• Next Earnings (Estimated): 8/12/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED PRODUCTS
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:ICCC
• CIK: 811641
• Web: www.immucell.com
• Phone: (207) 878-2770
• Fax: 207-878-2117
• Employees: 70
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): ($0.07)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$2.16 million
• Net Margins: -1.00%
• Pretax Margin: -0.96%
• Return on Equity: -1.02%
• Return on Assets: -0.61%

Debt

• Debt-to-Equity Ratio: 0.30
• Current Ratio: 4.12
• Quick Ratio: 2.21

Sales & Book Value

• Annual Sales: $26.49 million
• Price / Sales: 2.27
• Cash Flow: $0.07 per share
• Price / Cash Flow: 99.46
• Book Value: $3.09 per share
• Price / Book: 2.15

Miscellaneous

• Outstanding Shares: 9,040,000
• Free Float: 8,441,000
• Market Cap: $60.03 million
• Optionable: Not Optionable
• Beta: 0.32